{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":10,"sponsored":0,"items":[{"id":"n_zxhv4kngtnrrofk7anzq","seq":1387196,"kind":"article","title":"This week in charts: Kodiak's big comeback and Hengrui's dealmaking","url":"https://www.biopharmadive.com/news/week-in-charts-kodiaks-big-comeback-and-hengruis-dealmaking/831690","published":"2026-10-02T16:25:34Z","seen":"2026-10-02T16:25:34Z","lang":"en","source":{"id":"biopharmadive.com","name":"biopharmadive.com","domain":"biopharmadive.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Jonathan Gardner"],"entities":[{"id":"Q1778219","name":"Kodiak","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"}],"story":"st_zxhv4kngtnrrofk7anzq","category":"economy-business","category_p":0.71,"sentiment":"positive","tone":0.06,"political":0.01},{"id":"n_rrg4trlcz4eui6tzchja","seq":831253,"kind":"article","title":"北水周五起放假 恒指半日跌10點 藥股造好 恒瑞獲唱好升6% 歡創首掛飆近2倍｜港股開市","title_en":"North Water to start holiday on Friday, Hang Seng drops 10 points in half a day, pharmaceutical stocks perform well, Hengrui praised and rises 6%, Huaneng debuts up nearly 2 times | Hong Kong stock market","url":"https://www.stheadline.com/stock-market/3620867/%E5%8C%97%E6%B0%B4%E5%91%A8%E4%BA%94%E8%B5%B7%E6%94%BE%E5%81%87-%E6%81%92%E6%8C%87%E5%8D%8A%E6%97%A5%E8%B7%8C10%E9%BB%9E-%E8%97%A5%E8%82%A1%E9%80%A0%E5%A5%BD-%E6%81%92%E7%91%9E%E7%8D%B2%E5%94%B1%E5%A5%BD%E5%8D%876-%E6%AD%A1%E5%89%B5%E9%A6%96%E6%8E%9B%E9%A3%86%E8%BF%912%E5%80%8D%E6%B8%AF%E8%82%A1%E9%96%8B%E5%B8%82","summary":"國慶假期將至，北水將於周五開始放假至下周四復市，恒指今早低開129點，跌幅曾擴大至191點，低見24332點，其後逐步收窄失地並曾倒升35點，惟高位缺乏買盤，中午跌10點或0.04%，報24513點，半日成交金額887.66億元；科指半日跌6點或0.15%，報4243點。 建銀國際：恒指恐下試24000 建銀國際表示，港股仍受高油價、美債長端息率高企及盈利預期未見明顯改善所壓制，中美關係改善雖提供","published":"2026-09-30T04:15:33Z","seen":"2026-09-30T05:36:32Z","lang":"zh","country":"HK","source":{"id":"kite-stheadline-com-b401ae","name":"stheadline.com","domain":"stheadline.com","outlet":{"wikidata":"Q5241255","name":"Sing Tao Daily","type":"newspaper","designations":["daily newspaper"]}},"via":"kite-stheadline-com-b401ae","authors":["author"],"entities":[{"id":"Q15929632","name":"Hengrui","type":"org"},{"id":"Q842509","name":"China Huaneng Group Co., Ltd.","type":"org"}],"story":"st_hb7pt5wywm5efgic7uva","category":"economy-business","category_p":0.89,"sentiment":"positive","tone":0.37,"political":0.01},{"id":"n_26o63r52bpby4gkcbdbq","seq":724509,"kind":"article","title":"Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill","url":"https://www.biopharmadive.com/news/novo-hengrui-oral-obesity-drug-deal/831607","published":"2026-09-29T16:52:22Z","seen":"2026-09-29T16:52:22Z","lang":"en","source":{"id":"biopharmadive.com","name":"biopharmadive.com","domain":"biopharmadive.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Jonathan Gardner"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"}],"story":"st_gp7ki547mrf4cuuro2ia","category":"economy-business","category_p":0.75,"sentiment":"neutral","tone":0.16,"political":0.12},{"id":"n_2nmjbcnhv4mguryj2j3a","seq":704000,"kind":"article","title":"Novo Nordisk pagará até US$ 2,6 bi à chinesa Hengrui por direitos de pílula para perda de peso","title_en":"Novo Nordisk to pay up to $2.6 billion to China's Hengrui for weight loss pill rights","url":"https://redir.folha.com.br/redir/online/emcimadahora/rss091/*https://c-level.folha.uol.com.br/negocios/2026/09/novo-nordisk-pagara-ate-us26-bi-a-chinesa-hengrui-por-direitos-de-pilula-para-perda-de-peso.shtml","summary":"A Novo Nordisk pagará até US$ 2,6 bilhões (R$ 13,6 bilhões) à Jiangsu Hengrui Pharmaceuticals pelos direitos sobre um medicamento experimental para perda de peso, ampliando seu portfólio de produtos por meio de um segundo acordo de tratamento com GLP-1 com um parceiro chinês. Leia mais (09/29/2026 - 11h06)","published":"2026-09-29T14:06:00Z","seen":"2026-09-29T15:18:23Z","lang":"pt","country":"BR","source":{"id":"kite-folha-uol-com-br-a7488b","name":"folha.uol.com.br","domain":"feeds.folha.uol.com.br"},"via":"kite-folha-uol-com-br-a7488b","authors":["author"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"}],"story":"st_gp7ki547mrf4cuuro2ia","category":"economy-business","category_p":0.85,"sentiment":"neutral","tone":-0.09,"political":0.11},{"id":"n_wxk3bz3gfdfgdvycshoa","seq":688284,"kind":"article","title":"Novo mise sur une pilule anti-obésité du chinois Hengrui","title_en":"Novo bets on an anti-obesity pill from the Chinese Hengrui","url":"https://www.bluewin.ch/fr/infos/monde/novo-mise-sur-une-pilule-anti-ob-sit-du-chinois-hengrui-li.3618014","summary":"Le géant pharmaceutique danois a annoncé mardi un accord de licence avec Hengrui Pharma qui lui accorde les droits du laboratoire chinois, hors Chine, d'un traitement expérimental contre l'obésité.","published":"2026-09-29T13:37:43Z","seen":"2026-09-29T14:14:39Z","lang":"fr","country":"CH","source":{"id":"kite-bluewin-ch-5267ac","name":"bluewin.ch","domain":"bluewin.ch","outlet":{"wikidata":"Q886096","name":"Q886096","type":"other","designations":["business"]}},"via":"kite-bluewin-ch-5267ac","entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"}],"story":"st_wxk3bz3gfdfgdvycshoa","category":"economy-business","category_p":0.4,"category2":"health","sentiment":"neutral","tone":0.31,"political":0.08},{"id":"n_wagr7abbwthuucapx4ka","seq":670881,"kind":"article","title":"Novo Nordisk fecha acordo de até US$ 2,6 bi com chinesa Hengrui para remédio oral de perda de peso","title_en":"Novo Nordisk signs up to $2.6 billion agreement with Chinese Hengrui for oral weight loss medication","url":"https://valor.globo.com/empresas/noticia/2026/09/29/novo-nordisk-fecha-acordo-de-at-us-26-bi-com-chinesa-hengrui-para-remdio-oral-de-perda-de-peso.ghtml","summary":"A Novo assinou um contrato de licenciamento com a chinesa Hengrui Pharma para o desenvolvimento de um tratamento inovador voltado à perda de peso, em uma transação com valor potencial que pode alcançar até US$ 2,6 bilhões. Matéria exclusiva para assinantes. Para ter acesso completo, acesse o link da matéria e faça o seu cadastro.","published":"2026-09-29T12:00:04Z","seen":"2026-09-29T12:44:27Z","lang":"pt","country":"BR","source":{"id":"kite-pox-globo-com-4344ca","name":"pox.globo.com","domain":"pox.globo.com"},"via":"kite-pox-globo-com-4344ca","topics":["valor"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"},{"id":"Q29520","name":"China","type":"place"}],"image":"https://s2-valor.glbimg.com/qWfv2-JUpcdSpDGjw7Gx_-59Ghk=/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2026/H/H/qxqXR3RJWIuDlGOFWdnQ/original-2-.jpg","story":"st_pzrhzdphc3avaorpmhoa","category":"economy-business","category_p":0.78,"sentiment":"neutral","tone":0.22,"political":0.12},{"id":"n_5oecjoezr6kezpbo2e5q","seq":650677,"kind":"article","title":"Novo adquiere la licencia de un fármaco contra la obesidad por 2.300 millones a la empresa china Hengrui","title_en":"Novo acquires the license of an obesity drug for 2.3 billion from the Chinese company Hengrui","url":"https://www.infosalus.com/farmacia/noticia-novo-adquiere-licencia-farmaco-contra-obesidad-2300-millones-empresa-china-hengrui-20260929123414.html","summary":"Novo Nordisk ha adquirido los derechos exclusivos para desarrollar, fabricar y comercializar un medicamento de toma oral contra la obesidad, denominado HRS-1596, por un valor de 2.600 millones de dólares (2.300 millones de euros) a la empresa china Hengrui Pharma.","published":"2026-09-29T10:34:14Z","seen":"2026-09-29T11:15:46Z","lang":"es","source":{"id":"kite-infosalus-com-ae054a","name":"infosalus.com","domain":"infosalus.com"},"via":"kite-infosalus-com-ae054a","topics":["medicine","infosalus.com","farmacia"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"}],"image":"https://img.europapress.es/fotoweb/fotonoticia_20260929123414_120.jpg","story":"st_gp7ki547mrf4cuuro2ia","category":"economy-business","category_p":0.7,"category2":"health","sentiment":"positive","tone":0.29,"political":0.08},{"id":"n_hxju52soro4zvpa74xca","seq":633751,"kind":"article","title":"Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug","url":"https://www.fiercebiotech.com/biotech/novo-agrees-26b-deal-preclinical-glp-1gip-drug-demand-hengrui","published":"2026-09-29T09:54:17Z","seen":"2026-09-29T09:54:17Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["economy","science","health","business"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"}],"story":"st_hxju52soro4zvpa74xca","category":"economy-business","category_p":0.62,"sentiment":"neutral","tone":0.28,"political":0.17},{"id":"n_pzrhzdphc3avaorpmhoa","seq":621186,"kind":"article","title":"China's Hengrui licenses weight-loss drug to Denmark's Novo Nordisk in deal worth up to $2.6B","url":"https://www.aa.com.tr/en/health/chinas-hengrui-licenses-weight-loss-drug-to-denmarks-novo-nordisk-in-deal-worth-up-to-26b/4072336","summary":"Experimental once-weekly oral drug designed to reduce weight, improve blood sugar control","published":"2026-09-29T08:38:45Z","seen":"2026-09-29T08:54:17Z","lang":"en","country":"TR","source":{"id":"anadolu","name":"Anadolu Agency (English)","domain":"aa.com.tr"},"via":"anadolu","entities":[{"id":"Q15929632","name":"Hengrui","type":"org"},{"id":"Q818846","name":"Novo","type":"org"}],"mentions":2,"story":"st_pzrhzdphc3avaorpmhoa","category":"economy-business","category_p":0.85,"sentiment":"positive","tone":0.29,"political":0.08},{"id":"n_gp7ki547mrf4cuuro2ia","seq":644786,"kind":"article","title":"Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill","url":"https://www.aol.com/articles/chinas-hengrui-inks-2-6-044655000.html","published":"2026-09-29T04:46:00Z","seen":"2026-09-29T10:49:26Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["AOL"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q15929632","name":"Hengrui","type":"org"},{"id":"Q29520","name":"China","type":"place"}],"story":"st_gp7ki547mrf4cuuro2ia","category":"economy-business","category_p":0.86,"sentiment":"neutral","tone":-0.15,"political":0.12}]}